Aromatase inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Meg Taylor No edit summary |
||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{reflist}} | |||
Revision as of 02:15, 7 October 2013
Aromatase inhibitors, which inhibit the enzyme aromatase used biologically to produce estrogens, inhibit the biosynthetic production of estrogen steroids. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially breast cancer in postmenopausal women. At present, three AIs are approved by the FDA[1] :
- anastrazole (Arimidex®)
- exemestane (Aromasin®)
- letrozole (Femara®)